RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study
RIBOMIC Advances Pediatric Achondroplasia Treatment Study (via TipRanks Japan Auto-Generated Newsdesk • 8/2/24) “RIBOMIC Inc., a biopharmaceutical firm, has completed enrollment for its early Phase II study of umedaptanib pegol,…